Table 2 Demographic and clinical characteristics of NPSLE patients and controls
Variable | Category | NPSLE (n = 22) | Control (n = 22) |
|---|---|---|---|
Demographic variables | Age, years | 26 (18–40) | 27 (19.75–48) |
Gender (male/female) | 3/19 | 13/9 | |
SLE duration, month | 3.5 (0.5–12.0) | – | |
SLEDAI-2 K, median (range) | 16 (13–39) | – | |
Serum laboratory | IgG | 17.30 (8.93–33.41)* | 12.28 (10.68–13.77) |
IgM | 1.26(0.65–2.22) | 1.64 (0.92–2.75) | |
IgA | 2.31 (1.04–2.92) | 2.59(1.38–3.41) | |
C3, median (range),g/dL | 0.53 (0.18–0.77)* | 0.94 (0.71–1.30) | |
C4, median (range),g/dL | 0.06 (0.03–0.16)* | 0.22 (0.11–0.37) | |
CRP, median (range), mg/L | 5.46(3.50–34.55)* | 2.32 (1.13–4.03) | |
ANA | 22/22(100%) | 0/22 | |
anti-dsDNA | 12/22(54.6%) | 0/22 | |
anti-ribosomal P | 14/22(63.6%) | 0/22 | |
ACL/β-GP1/LA | 7/22 (31.9%) | 0/22 | |
Neuropsychiatric manifestations | Seizure disorders, n (%) | 5 (22.7%) | – |
Acute confusional state, n (%) | 7 (31.8%) | – | |
Cognitive impairment, n (%) | 5 (22.7%) | – | |
Cerebrovascular disease#, n (%) | 1 (4.5%) | ||
Myelopathy, n (%) | 2 (9.1%) | ||
Meningitis, n (%) | 1 (4.5%) | ||
Psychosis, n (%) | 1 (4.5%) | – | |
Routine parameters in CSF | Pressure (mmHg) | 185 (90–220) | 110 (85–160) |
Protein (mg/L) | 843 (617–1339) | 229 (196–307) | |
Glucose (mmol/L) | 3.25 (2–4.5) | 3.20 (2–4.0) | |
Chlorine (mmol/L) | 122 (114–129) | 123 (120–131) | |
Cell counts (10 6 / L) | 8.5 (2–47) | 4 (1–9) |